Following Democratic victories in the midterm elections that secured control of the House and Senate, the new majority holds significant leverage over federal healthcare policy. Health policy experts and former White House advisers indicate that Democrats intend to restore enhanced Affordable Care Act subsidies, reverse recent Medicaid cuts, and scrutinize the Trump administration’s health initiatives. However, any legislative action faces a high barrier: President Donald Trump has signaled he will use his veto power to block policies he opposes, creating a potential standoff over the future of healthcare coverage and costs.
The shift in congressional control introduces three physicians into the Senate and House who have been vocal critics of Health Secretary Robert F. Kennedy Jr. These lawmakers, including Senator-elect Annie Andrews of South Carolina, Senator-elect Abdul El-Sayed of Michigan, and Representative-elect Richard Pan of California, are expected to drive oversight efforts. Miranda Yaver, an assistant professor of health policy and management at the University of Pittsburgh, stated that the last two years have seen a transformation of the healthcare system that has been "immensely damaging," and she expects significant oversight to unpack those harms.
What the Right Is Saying
President Donald Trump has positioned himself as a dealmaker on certain healthcare issues while maintaining a firm stance against sweeping progressive changes. Ahead of the election, Trump stated he would brand himself "Mr. Veto" if Democrats took control of Congress, though he later said he would "probably" get along with the new majority. On prescription drug pricing, Trump has prioritized his discount website, TrumpRx, and "most favored nation" deals with manufacturers. Dr. Emanuel acknowledged that there is potential for agreement on lowering drug costs, given Trump’s focus on the issue during his second term.
However, skeptics on the right and within policy circles question the transparency of these executive actions. Barkett noted that the major drug pricing deals signed by Trump have not been publicly detailed, and it is unclear whether the drug manufacturers were significantly disadvantaged by them. Additionally, the Trump administration has already taken steps to crack down on prior authorization, a practice insurers use to require patient approval for treatments, which aligns with some Democratic goals but is framed by the administration as a necessary regulatory adjustment rather than a concession to opposition pressure.
What the Left Is Saying
House Minority Leader Hakeem Jeffries has identified restoring the expired enhanced ACA tax credits as a primary objective for Democrats in 2027. When these federal subsidies expired at the end of 2025, millions of Americans saw their monthly premium bills double or triple, leading approximately 3 million people to drop their coverage. Larry Levitt, executive vice president for health policy at KFF, noted that if a deal is reached, relief could be backdated to the beginning of 2027, providing refunds to those who paid higher premiums. Dr. Ezekiel Emanuel, a former special adviser for health policy during the Obama administration, supported pursuing reimplemented subsidies but warned against overreach, noting that half of all Americans receive insurance through employers.
Democrats also plan to challenge the Medicaid work requirements implemented under the Trump administration’s recent budget legislation. John Barkett, a former White House policy adviser under the Biden administration, described the upcoming legislative strategy as "farming" rather than "hunting," focusing on incremental changes and preparing the ground for future growth rather than seeking large, immediate victories that are likely to be vetoed. Senator-elect Andrews has specifically criticized Kennedy for overhauling the federal vaccine schedule and promoting medical disinformation, labeling him an "archnemesis" to public health.
What the Numbers Show
The expiration of enhanced ACA subsidies has had a measurable impact on enrollment and costs. Approximately 3 million individuals dropped their coverage after premiums rose sharply. For 2027, ACA premiums are projected to increase by double digits for the second consecutive year, driven by lower enrollment and rising healthcare costs, which has caused some major insurers to exit the market. In the realm of public health, the Centers for Disease Control and Prevention reported more than 4,850 measles cases in the current year, the highest number in at least 30 years, a statistic that critics attribute to changes in vaccine policy under Secretary Kennedy.
Regarding Medicaid, the new work requirements are expected to strip coverage from millions of people, largely due to administrative burdens rather than lack of employment. A federal judge in Boston recently blocked a policy from the Centers for Medicare & Medicaid Services that required "medically frail" patients to prove they were too impaired to meet work mandates, granting states an additional six months to implement a more lenient version. Ten states, including Georgia, Texas, and Wisconsin—which elected Democratic governors in the midterms—have not yet adopted the full Medicaid expansion under the ACA, though the removal of federal financial incentives for expansion complicates the path forward.
The Bottom Line
The new congressional dynamic sets the stage for a period of intense oversight and legislative maneuvering rather than immediate statutory overhaul. Democrats will likely use their committee powers to hold hearings, demand documents, and subpoena administration officials, particularly regarding Secretary Kennedy’s changes to vaccine schedules and the CDC advisory panel. While "Medicare for All" remains a symbolic goal for the progressive wing, its passage is unlikely under a Republican president. The central challenge for the new Democratic majority will be balancing the desire to reverse recent cuts with the political reality of a president who has explicitly stated his intent to veto significant legislative changes. Analysts suggest that the most likely outcomes will be partial victories on transparency and incremental adjustments to drug pricing and insurance rules, rather than a wholesale return to pre-2025 healthcare policy frameworks.